دورية أكاديمية
Case report: Exceptional and durable response to Radium-223 and suspension of androgen deprivation therapy in a metastatic castration-resistant prostate cancer patient
| العنوان: | Case report: Exceptional and durable response to Radium-223 and suspension of androgen deprivation therapy in a metastatic castration-resistant prostate cancer patient |
|---|---|
| المؤلفون: | Zacchi, Francesca, Macarena, Gonzalez, Semidey Raven, Maria Eugenia, Carles, Joan, Maldonado, Xavier, Perez-Lopez, Raquel, Mateo, Joaquin |
| المساهمون: | Institut Català de la Salut, Zacchi F Section of Innovation Biomedicine-Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Carles J, Gonzalez M, Maldonado X, Mateo J Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Perez-Lopez R Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Semidey ME Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus |
| المصدر: | Scientia |
| بيانات النشر: | Frontiers Media |
| سنة النشر: | 2024 |
| مصطلحات موضوعية: | Metàstasi, Marcadors bioquímics, Pròstata - Càncer - Tractament, Antiandrògens - Ús terapèutic, DISEASES::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Male::Prostatic Neoplasms::Prostatic Neoplasms, Castration-Resistant, CHEMICALS AND DRUGS::Hormones, Hormone Substitutes, and Hormone Antagonists::Hormone Antagonists::Androgen Antagonists, Other subheadings::Other subheadings::/therapeutic use, CHEMICALS AND DRUGS::Biological Factors::Biomarkers, DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales masculinos::neoplasias de la próstata::neoplasias prostáticas resistentes a la castración, COMPUESTOS QUÍMICOS Y DROGAS::hormonas, sustitutos de hormonas y antagonistas de hormonas::antagonistas de hormonas::antagonistas de andrógenos, Otros calificadores::Otros calificadores::/uso terapéutico, COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores, ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica |
| الوصف: | Bone metastases; Bone response; Metastatic castration-resistant prostate cancer ; Metástasis óseas; Respuesta ósea; Cáncer de próstata resistente a la castración metastásico ; Metàstasis òssies; Resposta òssia; Càncer de pròstata resistent a la castració metastàtic ; Despite the development of new therapies in the last few years, metastatic prostate cancer (PCa) is still a lethal disease. Radium-223 (Ra-223) is approved for patients with advanced castration-resistant prostate cancer (CRPC) with bone metastases and no visceral disease. However, patients' outcomes are heterogenous, and there is lack of validated predictive biomarkers of response, while biomarkers for early identification of patients who benefit from treatment are limited. This case report describes a remarkable and durable response to Ra-223 in a CRPC patient with bone metastases who had rapidly progressed to many previous therapies; this response is now lasting for 5 years even after having stopped backbone androgen deprivation therapy (ADT). Here, we present the clinical course of this exceptional response, as well as comprehensive genomic and histopathology analyses on sequential biopsies acquired before and after therapy. Additionally, we review current knowledge on predictive and response biomarkers to Ra-223 in metastatic prostate cancer. ; The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The authors acknowledge funding from CRIS Cancer Foundation (grant TCL_2020-10 to JM) and Fundación AECC (LABAE20019MATE to JM) and FERO Foundation. RP-L is supported by LaCaixa Foundation, a CRIS Foundation Talent Award TALENT19-05, the FERO Foundation, the Instituto de Salud Carlos III-Investigacion en Salud PI18/01395 and PI21/01019 and the Prostate Cancer Foundation 18YOUN19. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 2234-943X |
| العلاقة: | Frontiers in Oncology;14; https://doi.org/10.3389/fonc.2024.1331643Test; info:eu-repo/grantAgreement/ES/PE2013-2016/PI18%2F01395; info:eu-repo/grantAgreement/ES/PE2017-2020/PI21%2F01019; Zacchi F, Carles J, Gonzalez M, Maldonado X, Perez-Lopez R, Semidey ME, et al. Case report: Exceptional and durable response to Radium-223 and suspension of androgen deprivation therapy in a metastatic castration-resistant prostate cancer patient. Front Oncol. 2024 Mar 8;14:1331643.; https://hdl.handle.net/11351/11272Test |
| DOI: | 10.3389/fonc.2024.1331643 |
| الإتاحة: | https://doi.org/10.3389/fonc.2024.1331643Test https://hdl.handle.net/11351/11272Test |
| حقوق: | Attribution 4.0 International ; http://creativecommons.org/licenses/by/4.0Test/ ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.97A793B9 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 2234943X |
|---|---|
| DOI: | 10.3389/fonc.2024.1331643 |